This HTML5 document contains 33 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n9http://bio2rdf.org/drugbank:
n10http://linked.opendata.cz/resource/drugbank/drug/DB08927/identifier/wikipedia/
admshttp://www.w3.org/ns/adms#
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n7http://linked.opendata.cz/resource/drugbank/drug/DB08927/identifier/drugbank/
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
n2:DB08927
rdf:type
n3:Drug
n3:description
Amperozide is an atypical antipsychotic of the diphenylbutylpiperazine class which acts as an antagonist at the 5-HT2A receptor. It does not block dopamine receptors as with most antipsychotic drugs, but does inhibit dopamine release, and alters the firing pattern of dopaminergic neurons. It was investigated for the treatment of schizophrenia in humans, but never adopted clinically, its main use is instead in veterinary medicine, primarily in intensively farmed pigs, for decreasing aggression and stress and thereby increasing feeding and productivity. [Wikipedia]
n3:generalReferences
# Svartengren J, Simonsson P: Receptor binding properties of amperozide. Pharmacol Toxicol. 1990;66 Suppl 1:8-11. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2154737 # Meltzer HY, Zhang Y, Stockmeier CA: Effect of amperozide on rat cortical 5-HT2 and striatal and limbic dopamine D2 receptor occupancy: implications for antipsychotic action. Eur J Pharmacol. 1992 May 27;216(1):67-71. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/1388121 # Eriksson E: Amperozide, a putative anti-psychotic drug: uptake inhibition and release of dopamine in vitro in the rat brain. Life Sci. 1990;47(23):2111-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/1979998 # Yamamoto BK, Meltzer HY: The effect of the atypical antipsychotic drug, amperozide, on carrier-mediated striatal dopamine release measured in vivo. J Pharmacol Exp Ther. 1992 Oct;263(1):180-5. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/1403783 # Grenhoff J, Tung CS, Ugedo L, Svensson TH: Effects of amperozide, a putative antipsychotic drug, on rat midbrain dopamine neurons recorded in vivo. Pharmacol Toxicol. 1990;66 Suppl 1:29-33. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2304893 # Axelsson R, Nilsson A, Christensson E, Bjork A: Effects of amperozide in schizophrenia. An open study of a potent 5-HT2 receptor antagonist. Psychopharmacology (Berl). 1991;104(3):287-92. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/1924636 # Kyriakis SC, Martinsson K, Olsson NG, Bjork A: Thin sow syndrome (TSS): the effect of amperozide. Br Vet J. 1990 Sep-Oct;146(5):463-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/2224491 # Kyriakis SC, Olsson NG, Martinsson K, Bjork AK: Observations on the action of amperozide: are there social influences on sow-litter productivity? Res Vet Sci. 1991 Sep;51(2):169-73. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/1788479 # Papp I, Waller C, Biro O: [Practical experiences in the therapy of postweaning edema disease in piglets]. Berl Munch Tierarztl Wochenschr. 1996 Oct;109(10):385-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/8999770
n3:group
experimental
owl:sameAs
n9:DB08927
dcterms:title
Amperozide
adms:identifier
n7:DB08927 n10:Amperozide
n3:IUPAC-Name
n4:271B5D6D-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5D73-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5D72-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5D6F-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5D70-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5D71-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5D6C-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B5D79-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5D7A-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5D74-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5D75-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5D77-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5D76-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5D78-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
75558-90-6
n3:Bioavailability
n4:271B5D7F-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5D81-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5D82-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5D7E-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5D7D-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5D80-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5D6E-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5D7B-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5D7C-363D-11E5-9242-09173F13E4C5